12 completed, 12 terminated, 8 recruiting, 2 active not recruiting. 37 Phase 1, 14 Phase 2.
Follow abiraterone: new trials by email Literature Review of abiraterone trials Research Report on abiraterone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer INR731, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 | Recruiting | Novartis Pharmaceuticals | 208 | 2026-05-25 | 2026-10-23 |
| TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Tulmimetostat, Darolutamide, Abiraterone - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 181 | 2026-01-13 | 2026-09-29 |
| A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC AMO959, AAA617, Enzalutamide - PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 123 | 2025-12-05 | 2026-10-15 |
| Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer Xaluritamig, Darolutamide, Abiraterone - Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 1 | Recruiting | Amgen | 60 | 2025-10-07 | 2026-07-02 |
| A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) Docetaxel, Ifinatamab Deruxtecan, Opevesostat - Castration-Resistant Prostatic Cancer, Metastasis | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 360 | 2025-07-03 | 2026-10-09 |
| M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) M9466, Tuvusertib, Abiraterone acetate - Advanced Solid Tumor | Phase 1 | Active not recruiting | EMD Serono Research & Development Institute, Inc. | 60 | 2024-08-07 | 2026-09-09 |
| SNV1521 in Participants With Advanced Solid Tumors SNV1521, DB-1310, Abiraterone - Advanced Solid Tumor | Phase 1 | Recruiting | ParVation Therapeutics, Inc. | 400 | 2024-02-23 | 2026-06-25 |
| A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors DB-1311, Lopinavir and Ritonavir Tablets, itraconazole - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | DualityBio Inc. | 862 | 2023-08-17 | 2026-10-21 |
| Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer Abiraterone, Biospecimen Collection, Bone Scan - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 | Terminated | Emory University | 4 | 2023-08-03 | 2025-09-15 |
| Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log - Prostate Cancer, Prostate Adenocarcinoma | Phase 1 | Terminated | University of Chicago | 50 | 2023-01-24 | 2025-10-03 |
| Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer Bavdegalutamide, Abiraterone - Prostate Cancer Metastatic | Phase 1 | Completed | Arvinas Androgen Receptor, Inc. | 45 | 2022-05-13 | 2026-04-28 |
| A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors SM08502, Abiraterone, Prednisone - Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer | Phase 1 | Terminated | Biosplice Therapeutics, Inc. | 30 | 2021-11-03 | 2024-08-09 |
| A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer ARV-766, Abiraterone, Corticosteroid (e.g., prednisone/prednisolone) - Prostate Cancer Metastatic | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 164 | 2021-09-02 | 2026-08-18 |
| A Study of CC-90011 and Comparators in Participants With Prostate Cancer CC-90011, Abiraterone, Prednisone - Prostatic Neoplasms | Phase 1 | Completed | Celgene | 6 | 2021-07-28 | 2023-09-13 |
| Study of PCUR-101 in Combination With ADT in Patients With mCRPC PCUR-101, Dutasteride 0.5 mg, Abiraterone and Prednisone - Prostate Cancer | Phase 1 | Terminated | Pellficure Pharmaceuticals, Inc | 7 | 2021-03-30 | 2024-04-10 |
| The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC Coenzyme A Combined With Abiraterone, Abiraterone - Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Unknown | Jiangnan University | 50 | 2021-03-18 | 2021-04-09 |
| Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer Relugolix, Abiraterone, Prednisone - Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer | Phase 1 | Completed | Sumitomo Pharma America, Inc. | 48 | 2021-02-18 | 2025-08-17 |
| Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) XL102, Fulvestrant, Abiraterone - Neoplasm Malignant, Epithelial Ovarian Cancer | Phase 1 | Terminated | Exelixis | 52 | 2021-02-10 | 2024-05-14 |
| Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) Acapatamab, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Terminated | Amgen | 55 | 2021-01-15 | 2026-08-26 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
Showing 20 of 37. Sign in to see all of them.
Prostatic Neoplasms (22) · Neoplasm Metastasis (4) · Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Bites and Stings (2) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Genital Neoplasms, Male (2) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Myeloproliferative Disorders (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Primary Myelofibrosis (2)
Novartis Pharmaceuticals (4) · Amgen (3) · Dana-Farber Cancer Institute (2) · GlaxoSmithKline (2) · Arno Therapeutics (1) · Arvinas Androgen Receptor, Inc. (1) · AstraZeneca (1) · Biosplice Therapeutics, Inc. (1) · Celgene (1) · Constellation Pharmaceuticals (1) · DisperSol Technologies, LLC (1) · DualityBio Inc. (1) · EMD Serono Research & Development Institute, Inc. (1) · Emory University (1) · Epizyme, Inc. (1)
United States (32) · Australia (13) · Spain (12) · France (8) · United Kingdom (7) · Italy (6) · Canada (5) · Germany (5) · South Korea (5) · China (4) · Japan (4) · Belgium (3) · Netherlands (3) · Taiwan (3) · Brazil (2)
Bassel Nazha, MD, MPH (1) · Christopher Sweeney, MBBS (1) · Darrin Beaupre, MD, PhD, CMO (1) · David Burger, PhD (1) · Fred Zheng, MD, PhD (1) · Glenn Bubley, MD (1) · Jianqing Lin, MD (1) · Lara Davis, MD (1) · Lily Hu (1)
PMID 28178640, PMID 31527168, PMID 36572571, PMID 37060432, PMID 37507802, PMID 39863139, PMID 40180682
2025 (3), 2016 (1), 2017 (1), 2019 (1), 2023 (1), P30CA138292 (1)